TCGA-CN-5361-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.484018265
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ANGIOGENESIS+0.460
- NOTCH_SIGNALING+0.340
- COAGULATION+0.310
- HEDGEHOG_SIGNALING+0.290
- UV_RESPONSE_DN+0.270
- PROTEIN_SECRETION+0.250
- APICAL_JUNCTION+0.240
- PANCREAS_BETA_CELLS+0.190
- TGF_BETA_SIGNALING+0.190
Top 10 suppressed
- MYC_TARGETS_V1-0.490
- MYC_TARGETS_V2-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- TNFA_SIGNALING_VIA_NFKB-0.420
- E2F_TARGETS-0.370
- OXIDATIVE_PHOSPHORYLATION-0.350
- G2M_CHECKPOINT-0.280
- MTORC1_SIGNALING-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.210
- FATTY_ACID_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.853 |
| 2 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.818 |
| 3 | 60bc0507-0349-4154-9db4-8d93b3e8bdf5 | — | — | 0.810 |
| 4 | 1ab4a652-7fde-4128-ade4-0a1c56eede64 | — | — | 0.796 |
| 5 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.794 |
| 6 | 2b1fa47d-360a-4b4a-aa11-23bdb025b559 | — | — | 0.787 |
| 7 | MNG946 | — | — | 0.783 |
| 8 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.778 |
| 9 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.775 |
| 10 | TCGA-05-4405-01A-21R-1858-07 | — | cohortA1 | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.020 | Idelalisib | — uncovered |